Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Cytokinetics announced that CEO Robert I. Blum will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 11:00 AM ET. The live webcast can be accessed on the company's website, with a replay available for 90 days post-event.

Cytokinetics is a late-stage biopharmaceutical company focused on muscle activators and inhibitors for diseases affecting muscle performance. Their lead drug, omecamtiv mecarbil, has shown positive Phase 3 trial results for heart failure, while aficamten is being evaluated for hypertrophic cardiomyopathy.

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21^st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 11:00 AM ET.

Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Joanna Siegall
Associate Director, Corporate Communications, Investor Relations
(650) 624-1721

 

FAQ

What is Cytokinetics' participation in the Needham Conference on April 13, 2022?

Cytokinetics' CEO, Robert I. Blum, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 11:00 AM ET.

Where can I watch the Cytokinetics conference webcast?

The live webcast of Cytokinetics' participation can be accessed on the Investors & Media section of their website.

What are the main products being developed by Cytokinetics?

Cytokinetics is developing omecamtiv mecarbil for heart failure and aficamten for hypertrophic cardiomyopathy, alongside reldesemtiv for ALS.

What drug trials is Cytokinetics currently conducting?

Cytokinetics is conducting Phase 3 trials for aficamten (SEQUOIA-HCM) and reldesemtiv (COURAGE-ALS).

What is the significance of the GALACTIC-HF trial for Cytokinetics?

The GALACTIC-HF trial demonstrated positive results for omecamtiv mecarbil, marking a significant step towards potential commercialization for heart failure treatment.